June 10, 2020
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, June 2020

Strong EA research presence at ASCO 2020; the horrific killing of George Floyd; health equity and diversity in the field of oncology; the need for EA to participate in changing a specifically anti-racist culture and increase diversity and inclusion
June 10, 2020
Lung x-ray on iPad

Now Enrolling: EA5181 for Patients with Stage 3 Non-Small Cell Lung Cancer

This phase III trial is testing the antibody durvalumab added to standard chemoradiation followed by durvalumab for one year, compared to standard chemoradiation followed by one year of the antibody
June 10, 2020
PrECOG logo

Now Enrolling: PrE0905 for Acute Myeloid Leukemia

This phase II study is exploring the potent FLT3 inhibitor gilteritinib
June 10, 2020
E2112 video image

Trial Results: E2112 Finds No Significant Overall Survival Benefit With Entinostat/Exemestane in Advanced Breast Cancer

The study results, as well as correlative analyses, will be reported in an upcoming medical meeting
June 10, 2020

The Value of TMIST Compared to Other Breast Cancer Screening Studies

TMIST will provide data that is critical for relating the increased rate of detection of early breast cancers to the clinical outcomes of the screening population
June 10, 2020

ECOG-ACRIN Research at #ASCO20: How Twitter Helped Fill the Virtual Void

The new virtual meeting format, developed out of necessity, sparked interesting conversations